Imperial College London
Portrait Picture

Professor Anand Devaraj

Faculty of Medicine, National Heart & Lung Institute

Professor of Practice (Thoracic Radiology)
 
 
 
//

Contact

 

anand.devaraj Website

 
 
//

Location

 

South BlockRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Denton:2023:rheumatology/keac535,
author = {Denton, CP and Goh, NS and Humphries, SM and Maher, TM and Spiera, R and Devaraj, A and Ho, L and Stock, C and Erhardt, E and Alves, M and Wells, AU and SENSCIS, trial investigators},
doi = {rheumatology/keac535},
journal = {Rheumatology},
pages = {1870--1876},
title = {Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial},
url = {http://dx.doi.org/10.1093/rheumatology/keac535},
volume = {62},
year = {2023}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - OBJECTIVE: To assess associations between the extent of fibrotic interstitial lung disease (ILD) and forced vital capacity (FVC) at baseline and change in FVC over 52 weeks in patients with systemic sclerosis-associated ILD (SSc-ILD) in the SENSCIS trial. METHODS: We used generalised additive models, which involve few assumptions and allow for interaction between non-linear effects, to assess associations between the extent of fibrotic ILD on high-resolution computed tomography (HRCT), and the interplay of extent of fibrotic ILD on HRCT and FVC % predicted, at baseline and FVC decline over 52 weeks. RESULTS: In the placebo group (n = 288), there was weak evidence of a modest association between a greater extent of fibrotic ILD at baseline and a greater decline in FVC % predicted at week 52 (r: -0.09 [95% CI -0.2, 0.03]). Higher values of both the extent of fibrotic ILD and FVC % predicted at baseline tended to be associated with greater decline in FVC % predicted at week 52. In the nintedanib group (n = 288), there was no evidence of an association between the extent of fibrotic ILD at baseline and decline in FVC % predicted at week 52 (r: 0.01 [95% CI: -0.11, 0.12]) or between the interplay of extent of fibrotic ILD and FVC % predicted at baseline and decline in FVC % predicted at week 52. CONCLUSION: Data from the SENSCIS trial suggest that patients with SSc-ILD are at risk of ILD progression and benefit from nintedanib largely irrespective of their extent of fibrotic ILD at baseline. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT02597933.
AU  - Denton,CP
AU  - Goh,NS
AU  - Humphries,SM
AU  - Maher,TM
AU  - Spiera,R
AU  - Devaraj,A
AU  - Ho,L
AU  - Stock,C
AU  - Erhardt,E
AU  - Alves,M
AU  - Wells,AU
AU  - SENSCIS,trial investigators
DO  - rheumatology/keac535
EP  - 1876
PY  - 2023///
SN  - 1462-0324
SP  - 1870
TI  - Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial
T2  - Rheumatology
UR  - http://dx.doi.org/10.1093/rheumatology/keac535
UR  - https://www.ncbi.nlm.nih.gov/pubmed/36111858
UR  - https://academic.oup.com/rheumatology/article/62/5/1870/6701958
UR  - http://hdl.handle.net/10044/1/99837
VL  - 62
ER  -
Download